Director Declaration

GlaxoSmithKline PLC
03 July 2003

              GlaxoSmithKline plc Non-Executive Directors' details

The following details for Mr Lawrence Culp and Mr Crispin Davis are provided in
accordance with the requirements of the Financial Services Authority's Listing
Rules on their appointment to the Board of GlaxoSmithKline plc with effect from
1st July 2003.

Mr Culp - Non-Executive Director

Mr Culp was appointed a director of Danaher Corporation, a company incorporated
under the laws of Delaware in the USA, in May 2001. Danaher Corporation's stock
is listed on the New York Stock Exchange. He has not previously been a director
of a company incorporated within the UK.

Mr Culp does not hold or have any notifiable interests in any GlaxoSmithKline
plc Ordinary Shares or American Depositary Shares.

Mr Davis - Non-Executive Director

The following table shows Mr Davis' current and past directorships of publicly
quoted companies during the past five years.


      Company                                           Country of incorporation

Current directorships
Reed Elsevier plc                                             England & Wales
Reed Elsevier NV                                                Netherlands

Past directorships
Aegis Group plc                                              England & Wales

Mr Davis has an interest in 5,167 Ordinary Shares in GlaxoSmithKline plc of
which 3,008 shares are registered in his name and 2,159 shares in the name of
his wife, Mrs Jean Anne Davis. These shares were acquired prior to Mr Davis
being appointed to the Board of GlaxoSmithKline plc.



Paragraph 6.F.2 (b) to (g) Financial Services Authority's Listing Rules

Neither Messrs Culp nor Davis has any details to disclose in respect of
paragraph 6.F.2(b) to (g) of the Financial Services Authority's Listing Rules.





S M Bicknell

Company Secretary

3rd July 2003


                      This information is provided by RNS
            The company news service from the London Stock Exchange